GO
Loading...

Merck & Co Inc

More

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • *Sales of 5 key drugs seen at close to 4 bln eur in 2015. LEVERKUSEN, Germany, Feb 26- Germany's largest drugmaker Bayer said it expects underlying core earnings to increase by more than 10 percent this year, banking on a boost from new drugs such as stroke prevention pill Xarelto. The company is benefiting from a strong dollar in particular as North America accounts...

  • The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson& Johnson and Merck& Co.. Unlisted Mundipharma said on Wednesday that it is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of relevant...

  • The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson& Johnson and Merck& Co.. Unlisted Mundipharma said on Wednesday that it is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of relevant...

  • Feb 24- An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute. Patients were treated with the company's Prostvac vaccine, in addition to escalating doses of...

  • The Biomedical Advanced Research and Development Authority has told the company that its anti-Ebola treatments should be efficient as Mapp Biopharmaceutical's ZMapp. The number of new cases has plummeted but officials have said much work still needs to be done before the virus is snuffed out in Liberia, Guinea and Sierra Leone, the three worst affected...

  • Activists want 'imminent retirement' of Ariad CEO Friday, 20 Feb 2015 | 1:50 PM ET
    A chemist works in the lab of Ariad Pharmaceuticals.

    Sarissa Capital will nominate two directors to Ariad Pharmaceuticals' board and seek the "imminent retirement" of Chief Executive Harvey Berger.

  • PARIS, Feb 19- French drugmaker Sanofi on Thursday named Olivier Brandicourt, a Paris- educated doctor and head of Bayer AG's healthcare arm, as its chief executive officer. Brandicourt had been widely tipped to become Sanofi's new boss, a position that opened when Chris Viehbacher was suddenly sacked last year. "Olivier Brandicourt's strong experience...

  • BOSTON, Feb 13- A massive effective devaluation of Venezuela's bolivar currency will likely badly dent 2015 earnings at a swath of major U.S. companies. Currently those assets are valued based on the main official rate of 6.3 bolivars to the dollar, or a second rate at 12 bolivars. Some companies, such as diapers and tissue maker Kimberly-Clark Corp, had recently...

  • Between men and women, the better investors are... Friday, 13 Feb 2015 | 7:00 AM ET

    An exclusive analysis of more than 2.5 million portfolios tracked by SigFig found that, on average, women outperformed male investors.

  • Lightning Round: It's part of a major revolution Thursday, 12 Feb 2015 | 7:19 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • UPDATE 1-Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 12:06 PM ET

    Feb 12- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus. The company has the means to manufacture millions of doses of the vaccine every month and is seeking funding to develop it further, Chief Executive Stanley Erck told Reuters. Even as President Barack Obama...

  • Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 8:27 AM ET

    Feb 12- Novavax Inc has begun early-stage testing of its Ebola vaccine in humans, the company said, less than five months after entering the race to develop a shot for the deadly virus. Other potential vaccines include those being developed by a NewLink Genetics Corp and Merck& Co Inc collaboration and by Johnson& Johnson and Bavarian Nordic A/S.

  • CARACAS, Feb 10- Venezuela launched a "free" foreign exchange platform on Tuesday that will likely devalue the bolivar in efforts to bolster state coffers amid tumbling oil revenue, although it risks causing a spike in already soaring inflation. The change could lead to billions of dollars in write-downs by foreign corporations with exposure to Venezuela...

  • CARACAS, Feb 10- Venezuela on Tuesday launched a new foreign exchange platform that will likely devalue the bolivar heavily in efforts to bolster state coffers amid tumbling oil revenue, but risks a spike in already soaring inflation. "This third mechanism is open, free, in which bidders and buyers exchange offers," Marco said during a press conference with...

  • CARACAS, Feb 10- Venezuela on Tuesday will unveil a new foreign exchange system which is likely to ease the country's three-tiered currency controls but also mean a large devaluation of the bolivar currency. Finance Minister Rodolfo Marco and Central Bank President Nelson Merentes were to give details at a news conference at 11 a.m. local time, the government...

  • CARACAS, Feb 10- Venezuela on Tuesday will unveil a new foreign exchange system that is likely to ease the country's three-tiered currency controls but would also mean a hefty devaluation of the bolivar currency. Finance Minister Rodolfo Marco and Central Bank President Nelson Merentes were to hold a news conference at 11 a.m. local time on a "new exchange...

  • *All-Achillion combination could rival Gilead, AbbVie treatments. Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies. The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent...

  • Stocks close up, turning green for the year; Jobs eyed Thursday, 5 Feb 2015 | 4:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher, encouraged by stabilization in oil and shaking off concerns about Greece ahead of the all-important jobs report.

  • Halftime Report Final Trades Thursday, 5 Feb 2015 | 2:16 PM ET

    Today's 4 hottest trades from the Fast Money Halftime Report traders.